Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

NCT02647762 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT02647762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02647762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis
Lead sponsor
Can-Fite BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
October 30, 2017
Completion date
November 30, 2020
Enrollment
244 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis